Fig. 4From: Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasisThe local response maintenance rate of the GEF group and control group. The local response maintenance rate at 1 year was 83% and 42%, respectively (log-rank test p < 0.001)Back to article page